BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 32496902)

  • 1. Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.
    Salzer WL; Burke MJ; Devidas M; Dai Y; Hardy KK; Kairalla JA; Gore L; Hilden JM; Larsen E; Rabin KR; Zweidler-McKay PA; Borowitz MJ; Wood B; Heerema NA; Carroll AJ; Winick N; Carroll WL; Raetz EA; Loh ML; Hunger SP
    J Clin Oncol; 2020 Aug; 38(23):2628-2638. PubMed ID: 32496902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
    Matloub Y; Lindemulder S; Gaynon PS; Sather H; La M; Broxson E; Yanofsky R; Hutchinson R; Heerema NA; Nachman J; Blake M; Wells LM; Sorrell AD; Masterson M; Kelleher JF; Stork LC;
    Blood; 2006 Aug; 108(4):1165-73. PubMed ID: 16609069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M
    J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
    Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
    Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
    Dunsmore KP; Winter SS; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Rabin KR; Zweidler-Mckay PA; Raetz EA; Loh ML; Schultz KR; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2020 Oct; 38(28):3282-3293. PubMed ID: 32813610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
    Winick N; Devidas M; Chen S; Maloney K; Larsen E; Mattano L; Borowitz MJ; Carroll A; Gastier-Foster JM; Heerema NA; Willman C; Wood B; Loh ML; Raetz E; Hunger SP; Carroll WL
    J Clin Oncol; 2017 Aug; 35(22):2527-2534. PubMed ID: 28535084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report.
    Laver JH; Barredo JC; Amylon M; Schwenn M; Kurtzberg J; Camitta BM; Pullen J; Link MP; Borowitz M; Ravindranath Y; Murphy SB; Shuster J
    Leukemia; 2000 Mar; 14(3):369-73. PubMed ID: 10720128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
    Stark B; Sharon R; Rechavi G; Attias D; Ballin A; Cividalli G; Burstein Y; Sthoeger D; Abramov A; Zaizov R
    Cancer; 2000 Jan; 88(1):205-16. PubMed ID: 10618625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.
    Kadan-Lottick NS; Brouwers P; Breiger D; Kaleita T; Dziura J; Northrup V; Chen L; Nicoletti M; Bostrom B; Stork L; Neglia JP
    J Clin Oncol; 2009 Dec; 27(35):5986-92. PubMed ID: 19884541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Münster) Relapse Study Group.
    Bührer C; Hartmann R; Fengler R; Schober S; Arlt I; Loewke M; Henze G
    Blood; 1994 Jun; 83(12):3468-72. PubMed ID: 8204875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232.
    Larsen EC; Devidas M; Chen S; Salzer WL; Raetz EA; Loh ML; Mattano LA; Cole C; Eicher A; Haugan M; Sorenson M; Heerema NA; Carroll AA; Gastier-Foster JM; Borowitz MJ; Wood BL; Willman CL; Winick NJ; Hunger SP; Carroll WL
    J Clin Oncol; 2016 Jul; 34(20):2380-8. PubMed ID: 27114587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ
    J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.
    Tubergen DG; Gilchrist GS; O'Brien RT; Coccia PF; Sather HN; Waskerwitz MJ; Hammond GD
    J Clin Oncol; 1993 Mar; 11(3):520-6. PubMed ID: 8445427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group.
    Tsurusawa M; Katano N; Yamamoto Y; Hirota T; Koizumi S; Watanabe A; Takeda T; Hatae Y; Yatabe M; Mimaya J; Gushiken T; Nishi K; Anami K; Kikuta A; Kanegane H; Asami K; Nishikawa K; Sekine I; Kawano Y; Iwai A; Furuyama T; Ijichi O; Miyake M; Mugishima H; Fujimoto T
    Med Pediatr Oncol; 1999 Apr; 32(4):259-6. PubMed ID: 10102019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
    Kaleita TA; Reaman GH; MacLean WE; Sather HN; Whitt JK
    Cancer; 1999 Apr; 85(8):1859-65. PubMed ID: 10223582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG.
    Burke MJ; Salzer WL; Devidas M; Dai Y; Gore L; Hilden JM; Larsen E; Rabin KR; Zweidler-McKay PA; Borowitz MJ; Wood B; Heerema NA; Carroll AJ; Winick N; Carroll WL; Raetz EA; Loh ML; Hunger SP
    Haematologica; 2019 May; 104(5):986-992. PubMed ID: 30545921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.